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OBJECTIVES This study was undertaken to determine whether atherosclerosis of the ascending aorta is a
predictor of long-term neurologic events and mortality.
BACKGROUND Atherosclerosis of the thoracic aorta has been recently considered a significant predictor of
neurologic events and peripheral embolism, but not of long-term mortality.
METHODS Long-term follow-up (a total of 5,859 person-years) was conducted of 1,957 consecutive
patients $50 years old who underwent cardiac surgery. Atherosclerosis of the ascending aorta
was assessed intraoperatively (epiaortic ultrasound) and patients were divided into four groups
according to severity (normal, mild, moderate or severe). Carotid artery disease was evaluated
(carotid ultrasound) in 1,467 (75%) patients. Cox proportional-hazards regression analysis
was performed to assess the independent effect of predictors on neurologic events and
mortality.
RESULTS A total of 491 events occurred in 472 patients (neurologic events 92, all-cause mortality 399).
Independent predictors of long-term neurologic events were: hypertension (p 5 0.009),
ascending aorta atherosclerosis (p 5 0.011) and diabetes mellitus (p 5 0.015). The
independent predictors of mortality were advanced age (p , 0.0001), left ventricular
dysfunction (p , 0.0001), ascending aorta atherosclerosis (p , 0.0001), hypertension (p 5
0.0001) and diabetes mellitus (p 5 0.0002). There was .1.5-fold increase in the incidence
of both neurologic events and mortality as the severity of atherosclerosis increased from
normal-mild to moderate, and a greater than threefold increase in the incidence of both as the
severity of atherosclerosis increased from normal-mild to severe.
CONCLUSIONS Atherosclerosis of the ascending aorta is an independent predictor of long-term neurologic
events and mortality. These results provide additional evidence that in addition to being a
direct cause of cerebral atheroembolism, an atherosclerotic ascending aorta may be a marker
of generalized atherosclerosis and thus of increased morbidity and mortality. (J Am Coll
Cardiol 1999;33:1308–16) © 1999 by the American College of Cardiology
Although embolism from the heart and/or carotid arteries is
a common cause of neurologic events, the cause of stroke
remains elusive in many patients (1–12). Analysis of data
from The National Institute of Neurological and Commu-
nicative Disorders and Stroke (NINCDS) Data Bank, a
large prospective study of over 1,800 patients, showed that
40% of cases of cerebral infarction were of “undetermined
cause” (13). An association between atherosclerotic disease
of the thoracic aorta and cerebral and peripheral embolism
(14–20) has been speculated for years, but the importance of
the thoracic aorta as a source of cerebral and vascular emboli
has been ascertained only recently (21–36).
Our group and others have shown that atherosclerosis of
the ascending aorta is an independent predictor of periop-
erative stroke and postoperative renal dysfunction in pa-
tients undergoing cardiac surgery (21–27). Amarenco et al.
showed in an autopsy study that ulcerated plaques in the
ascending aorta and aortic arch were significantly more
prevalent in those who had suffered cerebral embolic events
compared with those without such plaques (28). Three
recent studies, in which the majority of patients who had
sustained a recent stroke were followed prospectively, have
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shown an association between aortic arch atherosclerosis
and cerebral and/or peripheral embolic events (33–35).
However, an association between atherosclerosis of the
thoracic aorta and long-term mortality has not been shown.
In this prospective study, we followed a cohort of 1,957
consecutive patients who underwent evaluation of their
ascending aortas with epiaortic ultrasound at the time of
cardiac surgery to determine the prognostic significance of
atherosclerosis of this vessel as a predictor of long-term
neurologic events and mortality. Our hypothesis was that
increasing severity of atherosclerosis of the ascending aorta
would be a significant and independent predictor of both
events.
METHODS
Patient population. The study population consisted of
1,969 consecutive patients $50 years old (mean 68 6 9
years, range 50 to 91) undergoing cardiac surgery and
intraoperative evaluation of the ascending aorta with epi-
aortic ultrasound at Barnes-Jewish Hospital during the
period from January 1990 to May 1994. Long-term
follow-up was complete in 1,957 patients. The cardiac
surgical procedures performed in these patients included:
coronary artery bypass graft (CABG) surgery in 1,472
(75.2%), valve repair or replacement in 224 (11.5%) and
CABG and valve surgery in 261 (13.3%). Carotid endar-
terectomy or graft replacement of the ascending aorta was
performed in combination with one of the above procedures
in 65 (3.3%) and 47 (2.4%) patients, respectively. The study
protocol was approved by the Human Studies Committee at
Washington University Medical Center.
Variables analyzed. At the time of cardiac surgery, the
following characteristics were prospectively recorded: 1) age;
2) gender; 3) body mass index (kg/m2); a history of any of
the following (requiring treatment): 4) atrial fibrillation, 5)
hypertension, and 6) diabetes mellitus; 7) history of smok-
ing, 8) use of anticoagulants (warfarin and/or aspirin); 9)
presence of mitral stenosis (mitral valve area ,2 cm2); 10)
left ventricular (LV) function; 11) extent of coronary artery
disease (CAD); 12) extent of carotid artery disease; and 13)
serum cholesterol level. The LV function was assessed by
angiography or by echocardiography according to the Cor-
onary Artery Surgery Study, based on left ventricular ejec-
tion fraction (LVEF), as follows: LVEF .55% (score of
5) 5 normal; 40% to 54% (score 6–10) 5 mild dysfunction;
25% to 39% (score of 11–15) 5 moderate dysfunction, and
,24% (score .16) 5 severe dysfunction (37).
Ultrasonic methods. Ultrasonic epiaortic imaging of the
ascending aorta was performed during cardiac surgery in
each patient by use of a 7-MHz linear ultrasound transducer
(Acuson, Mountain View, California) inserted in a sterile
sheath and placed directly over this vessel, as previously
described (21,24–26,38). In brief, transverse and longitudi-
nal images were obtained from the level of the aortic root to
the level of the proximal aortic arch, just distal to the
innominate artery. The ultrasonic images were evaluated for
the presence of atherosclerosis by two observers blinded to
the clinical data, as follows: 1) normal aorta (no intimal
thickening), 2) mild atherosclerosis (,3 mm intimal thick-
ening without intimal irregularities), 3) moderate aortic
atherosclerosis (intimal thickening $3 mm, with diffuse
irregularities and/or calcification) and 4) severe atheroscle-
rosis (.5 mm intimal thickening and one or more of the
following: large protruding or mobile atheromatous debris,
ulcerated plaques and/or thrombi).
Carotid artery Doppler and duplex ultrasound was per-
formed in all patients $65 years old and in younger patients
with carotid bruits and/or symptoms or a history of neuro-
logic events, including transient ischemic attack (TIA) and
stroke. Carotid artery stenosis was graded based on results
of the carotid artery ultrasound performed in the longitu-
dinal and cross-sectional axes, as previously described
(39,40): 1) insignificant or no disease (luminal narrowing
#50%), 2) moderate disease (luminal narrowing .50% but
,80%), 3) severe disease (luminal narrowing $80% but
#99%) and 4) complete occlusion. For the purpose of
analysis, severe disease and complete occlusion were com-
bined.
Long-term follow-up. Each patient completed a question-
naire to identify those who had suffered a neurologic event
such as stroke or TIA during the follow-up period. A stroke
was defined as any neurologic impairment of motor, sensory
or cognitive function that persisted .24 h, or was associated
with death within 24 h, and that could not be explained by
other neurologic (ie, dementia, head trauma), and/or med-
ical (ie, metabolic abnormalities, drugs) etiologies; and a
TIA as neurologic impairment that resolved within 24 h,
and was unexplained by other neurologic and/or medical
etiologies. All neurologic events were confirmed by the
attending neurologist who cared for the patient at the time
of the event, or were documented in the medical records,
including results of computed tomography or magnetic
resonance imaging of the brain. Death was investigated
through a relative, the primary care physician or the hospital
records. In all instances, death was documented by the death
certificate. Three mailings of the questionnaire were sent
within a six-month period; 1,676 (85%) of the patients
responded, and for those who did not, a search of the
National Death Index was performed, which yielded infor-
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft
CAD 5 coronary artery disease
FAPS 5 French Aortic Plaques in Stroke study
LV 5 left ventricle
LVEF 5 left ventricular ejection fraction
TEE 5 transesophageal echocardiography
TIA 5 transient ischemic attack
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mation on 281 (14%) of the patients. Long-term follow-up
was unavailable on 12 patients (0.6% of the population);
data from these patients were excluded from the analysis.
The duration of follow-up was recorded as that from the day
of cardiac surgery to the date of patient contact, the date of
the neurologic event or the date of death. The mean
follow-up time was 3.0 6 1.9 years (range 0.1 to 7.6 years).
Statistical analysis. Data were analyzed with SAS version
6.11 (SAS Institute, Carey, North Carolina) and expressed
as the mean 6 SD. The association between the four
categorical measurements of severity of atherosclerosis of
the ascending aorta and the continuous variables was ana-
lyzed by analysis of variance (ANOVA). Wilcoxon’s test was
used to assess the relationship between ascending aortic
atherosclerosis and all dichotomous variables. Kaplan-Meier
survival analysis was used to describe the time to the first
event (neurologic events and all-cause mortality). Compar-
isons of survival curves were performed by use of a log-rank
test. In all event-specific survival analyses, data were cen-
sored at the time of death if the patient had not previously
suffered a neurologic event. A Cox proportional-hazards
multivariate regression analysis was used to assess the
independent significance of six predefined potential predic-
tors of the composite measure of neurologic events, all-cause
mortality and all events. In these regression analyses, find-
ings with respect to severity of atherosclerosis of the
ascending aorta were grouped into three categories: normal-
mild, moderate and severe. The normal and mild categories
were grouped together for two reasons: it led to a better
regression fit, and there were no differences between these
two groups. A p value ,0.05 was indicative of a statistically
significant difference.
RESULTS
Of the 1,957 patients for whom follow-up data regarding
neurologic events and death were available, 1,147 (58.6%)
had a normal ascending aorta, 461 (23.5%) had mild
atherosclerosis, 250 (12.8%) had moderate atherosclerosis
and 99 (5.1%) had severe atherosclerosis of the ascending
aorta. The baseline characteristics of the study patients
according to the severity of atherosclerosis of the ascending
aorta are listed in Table 1. Increasing severity of ascending
aorta atherosclerosis was associated with increasing age of
the patient, lower body mass index, history of smoking,
increased severity of carotid artery disease and higher serum
cholesterol levels. Patients with significant atherosclerosis of
the ascending aorta also tended to use less aspirin.
During the follow-up period, 92 neurologic events and
399 deaths occurred. Univariate predictors of long-term
neurologic events, all-cause mortality and all events (neuro-
logic events and all-cause mortality) are listed in Table 2.
Univariate predictors for neurologic events were male gen-
der; history of atrial fibrillation, hypertension and diabetes
mellitus; use of warfarin; severe carotid artery disease; and
severe atherosclerosis of the ascending aorta. Univariate
predictors of all-cause mortality were advanced age; male
gender; lower body mass index; history of atrial fibrillation,
hypertension and diabetes mellitus; LV dysfunction; severe
Table 1. Baseline Patient Characteristics According to Severity of Ascending Aorta Atherosclerosis
Variable
All patients
(n 5 1,957)
Severity of Ascending Aorta Atherosclerosis
p value*
Normal
(n 5 1,147)
Mild
(n 5 461)
Moderate
(n 5 250)
Severe
(n 5 99)
Age, years 68.3 6 8.5 67 6 8 69 6 9 71 6 8 72 6 8 , 0.0001
Male 64.1% 65.6% 61.2% 64.8% 58.6% 0.133
Body mass index, kg/m2 26.8 6 4.6 27.1 6 4.6 26.6 6 4.4 25.6 6 4.4 26.4 6 5.6 , 0.0001
Atrial fibrillation 12.6% 13.4% 10.7% 11.7% 14.1% 0.340
Hypertension 62.9% 62.8% 60.1% 65.4% 69.7% 0.563
Diabetes mellitus 27.2% 27.2% 27.9% 27.0% 23.5% 0.814
Smoking 45.4% 41.2% 46.1% 56.5% 62.6% , 0.0001
Warfarin 9.3% 8.9% 9.2% 12.5% 8.3% 0.34
Aspirin 56.3% 57.8% 56.2% 53.0% 47.5% 0.051
Mitral stenosis 2.8% 3.7% 1.7% 2.0% 0% 0.006
Left ventricular function† 9.4 6 4.0 9.3 6 3.9 9.1 6 3.9 9.5 6 4.0 10.5 6 4.3 0.0810
Extent of CAD, No. vessels 2.65 6 6.1 2.64 6 .63 2.64 6 .60 2.69 6 .56 2.70 6 .57 0.11
Carotid artery stenosis:‡
Normal-mild 76% 80% 78% 66% 63%
Moderate 18% 14% 18% 26% 30%
Severe 6% 6% 4% 8% 8% , 0.0001
Serum cholesterol, mg/dL 210 6 49 207 6 46 213 6 45 214 6 51 223 6 48 0.004
Data are mean 6 SD
* p values refer to comparisons between all four groups. †Mean left ventricular score (CASS; ref. 37). ‡More severe of right or left carotid artery stenosis.
CAD 5 coronary artery disease.
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carotid artery disease; lower serum cholesterol level; and
severe atherosclerosis of the ascending aorta. Use of aspirin
was associated with a lower incidence of all-cause mortality.
The event rates according to the severity of ascending aorta
atherosclerosis are listed in Table 3. The total number of
neurologic events during follow-up was significantly
higher in the group with severe ascending aortic athero-
sclerosis (p 5 0.05). The neurologic events, mortality and
the all-event rates significantly and incrementally in-
creased with increases in severity of ascending aortic
atherosclerosis.
When stratified by extent of atherosclerosis, the Kaplan-
Meier survival curves for neurologic events and all-cause
mortality varied significantly with severity of disease (Fig.
1). Univariate analyses indicated that for both outcomes (ie,
neurologic events and all-cause mortality), there were con-
sistent and statistically significant associations between ad-
verse outcome and increasing severity of ascending aortic
Table 2. Univariate Predictors of Long-Term Neurologic Events, All-cause Mortality, and All Events
Variable
Neurologic Event All-cause Mortality All Events
No
(n 5 1,865)
Yes
(n 5 92)
No
(n 5 1,558)
Yes
(n 5 399)
No
(n 5 1485)
Yes
(n 5 472)
Age, years 68.2 6 8.6 69.5 6 7.9 67.4 6 8.6 71.6 6 7.7* 67.4 6 8.6 71.0 6 7.8*
Male 64.6% 54.4%§ 65% 60.4%§ 64.9% 61.4%§
Body mass index 26.8 6 4.6 26.1 6 4.0 27.0 6 4.4 26.0 6 5.1† 27.0 6 4.5 26.2 6 5.0
Atrial fibrillation 12.3% 17.4%§ 10.6% 20.4%* 10.6% 18.7%*
Hypertension 62.2% 76.1%‡ 60.2% 73.2%* 59.6% 73.3%*
Diabetes mellitus 26.7% 35.9%† 24.5% 37.6%* 24.3% 36.2%*
Smoking 45.5% 42.4% 44.0% 50.9% 43.8% 50.2%
Warfarin 7.8% 41.4%* 8.7% 13.0% 6.5% 21.4%*
Aspirin 56.5% 51.1% 58.7% 46.7%* 58.9% 48.0%*
Mitral stenosis 2.7% 4.3% 2.9% 2.5% 3.0% 2.3%
Left ventricular function 9.3 6 3.9 9.6 6 4.3 9.1 6 3.8 10.5 6 4.3* 9.1 6 3.8 10.3 6 4.3*
Extent of CAD:
1 vessel 7.2% 9.9% 7.2% 7.6% 7.2% 7.6%
2 vessels 20.4% 14.8% 19.5% 22.7% 20.1% 20.4%
3 vessels 72.4% 75.3% 73.3% 69.7% 72.7% 72.0%
Carotid artery disease:
Normal-mild 76.2% 67.1% 78.2% 70.6% 78.7% 70.3%
Moderate 17.4% 21.0% 16.3% 21.8% 16.2% 21.2%
Severe 5.7% 11.8%‡ 5.5% 7.6%§ 5.1% 8.5%
Cholesterol, mg/dL 210 6 47 215 6 46 211 6 45 206 6 54§ 211 6 45 206 6 52§
Atherosclerosis Ascending Aorta:
Normal-mild 82.6% 73.9% 85.3% 69.3% 86.6% 71.4%
Moderate 12.6% 15.2% 11.1% 19.3% 10.8% 18.9%
Severe 4.8% 10.9%§ 3.6% 10.8%† 3.6% 9.7%*
*p , 0.0001, yes vs. no. †p , 0.001, yes vs. no. ‡p , 0.01, yes vs. no. §p , 0.05, yes vs. no. Data are mean 6 SD.
CAD 5 coronary artery disease.
Table 3. Event Rates in the Study Patients According to Severity of Ascending Aorta
Atherosclerosis
Event
Severity of Ascending Aorta Atherosclerosis
p
value
Normal
(n 5 1,147)
Mild
(n 5 461)
Moderate
(n 5 250)
Severe
(n 5 99)
Neurologic:
Stroke 37 (3.2%) 17 (3.7%) 11 (4.4%) 9 (9.0%)
TIA 14 (1.2%) 2 (0.4%) 3 (1.2%) 1 (1.0%)
Total 49 (4.3%) 19 (4.1%) 14 (5.6%) 10 (10.1%) 0.05
Death:
Total 177 (15.4%) 102 (22.1%) 77 (30.8%) 43 (43.4%) , 0.0001
All events* 220 (19.2%) 117 (25.4%) 89 (35.6%) 46 (46.5%) , 0.0001
*Includes neurologic events and all-cause death.
TIA 5 transient ischemic attack.
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atherosclerosis, and although the significant association was
apparent early, it continued to increase throughout the
follow-up period.
Multivariate Cox regression analysis was performed to
define predictive variables that had an independent associ-
ation with each of the three outcomes (Table 4). Advanced
age, LV dysfunction, atherosclerosis of the ascending aorta,
hypertension and diabetes mellitus showed a highly signif-
icant independent association with all events (Table 4). For
example, the risk ratio for aortic atherosclerosis indicated
Figure 1. Kaplan-Meier analysis of survival without neurologic events (A) and without all cause-mortality (B), according to severity of
atherosclerosis of the ascending aorta (normal, mild, moderate, severe).
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that moderate atherosclerosis was associated with an in-
crease of 1.30 in the risk of an event compared with
normal-mild disease. However, the risk ratio was 1.7 times
higher (1.30 3 1.30) for those with severe atherosclerosis
than for those with normal-mild atherosclerosis. Advanced
age, ascending aorta atherosclerosis, LV dysfunction, hyper-
tension and diabetes mellitus also were significantly and
independently associated with all-cause mortality (Table 4).
Hypertension, atherosclerosis of the ascending aorta and
diabetes mellitus were the only significant independent
predictors of neurologic events (Table 4).
The incidence of long-term events per 100 person-years
of follow-up according to severity of ascending aorta ath-
erosclerosis is listed in Table 5. There was a greater than
1.5-fold increase in the incidence of both neurologic events
and mortality as the severity of atherosclerosis increased
from normal-mild to moderate, and a greater than threefold
increase in the incidence of both as the severity of athero-
sclerosis increased from normal-mild to severe.
DISCUSSION
In this prospective study, long-term follow-up was per-
formed in 1,957 patients (mean duration 3.0 6 1.9 years)
for the development of neurologic events and all-cause
mortality. A statistically significant association was found
between hypertension, atherosclerosis of the ascending
aorta, diabetes mellitus and the subsequent occurrence of
neurologic events; and between advanced age, LV dysfunc-
tion, atherosclerosis of the ascending aorta, hypertension,
diabetes mellitus and the occurrence of all-cause mortality.
Patients with severe atherosclerosis of the ascending aorta
were found to have the highest incidence of neurologic
events and of all-cause mortality, and these incidence rates
were three-times higher than in patients with normal aortas,
even after correcting for variables known to be associated
with an increased incidence of these events, such as age,
carotid artery disease and atrial fibrillation. These find-
ings are in agreement with recent prospective studies that
Table 4. Independent Predictors of Long-Term Neurologic Events, All-cause Mortality, and All
Events
Variable
Chi
square RR 95% CI p value
All events (number of events 5 472)
Age* 37.1 1.43 1.27–1.60 , 0.0001
Left ventricular function† 32.8 1.39 1.24–1.56 , 0.0001
Ascending aorta atherosclerosis 30.0 1.3 1.19–1.44 , 0.0001
Hypertension 20.7 1.64 1.32–2.02 , 0.0001
Diabetes mellitus 11.9 1.41 1.16–1.72 0.0006
All-cause mortality (number of deaths 5 399)
Age* 47.2 1.56 1.37–1.77 , 0.0001
Ascending aorta atherosclerosis 40.0 1.38 1.25–1.53 , 0.0001
Left ventricular function† 35.5 1.45 1.28–1.64 , 0.0001
Hypertension 14.5 1.57 1.24–1.98 0.0001
Diabetes mellitus 14.3 1.51 1.22–1.87 0.0002
Neurologic events (number of neurologic events 5 92)
Hypertension 6.84 1.91 1.18–3.11 0.009
Ascending aorta atherosclerosis 6.52 1.31 1.06–1.62 0.011
Diabetes mellitus 5.97 1.72 1.11–1.64 0.015
*The risk ratio associated with age is the increased risk that is associated with a 10-year increase. †Left ventricular function based
on the CASS score (37).
RR 5 risk ratio; CI 5 confidence interval.
Table 5. Incidence of Long-Term Events According to Severity of Ascending Aorta
Atherosclerosis
Severity of
ascending aorta
atherosclerosis
Neurologic Events All-cause Mortality
No. of
events
Incidence per
100 person-years
of follow-up
No. of
events
Incidence per
100 person-years
of follow-up
Normal-mild 68 1.8 279 4.3
Moderate 14 2.9* 77 8.3‡
Severe 10 5.8† 43 14.3§
Increased incidence: *for normal-mild to moderate is 1.6; †for normal-mild to severe is 3.1; ‡for normal-mild to moderate is 1.9;
§for normal-mild to severe is 3.4.
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show a high recurrence rate of brain infarction in patients
with large plaques in the aortic arch (33–35), but this is
the first prospective study to show that ascending aorta
atherosclerosis is an independent predictor of long-term
mortality.
Importance of hypertension, diabetes mellitus and ath-
erosclerosis of the ascending aorta as predictors of stroke.
The role of hypertension as the most powerful risk factor for
stroke, and the reduction of this risk with adequate therapy,
has been documented in numerous studies (41–45). Simi-
larly, but to a lesser extent, diabetes mellitus has been
associated with increased risk of stroke and a poorer
prognosis after stroke (46–48). Thus, it is not surprising
that these two risk factors, in addition to atherosclerosis of
the ascending aorta, were the most significant predictors of
neurologic events in the present study. Numerous case
reports have identified an atherosclerotic thoracic aorta as a
likely source of arterial embolism to the brain and peripheral
vessels (14–19,31,49–50), and have been documented to
occur spontaneously (20), after initiation of anticoagulation
(51,52), in association with cardiac surgery (21–25,53), and
after invasive procedures (54). Atherosclerosis of the as-
cending aorta is a risk factor that has an independent
association with previous cerebrovascular events (26). A
recent autopsy study showed that the presence of ulcerated
plaques in the ascending aorta and/or the aortic arch was
associated with a significantly greater prevalence of cerebral
embolic events than that in the absence of such plaques (28).
In addition, three recent prospective studies have shown an
association between an atherosclerotic thoracic aorta (de-
tected by transesophageal echocardiography [TEE]), and
cerebral and/or peripheral vascular ischemic events (33–35).
Our findings support the results of these three studies,
but differ in several respects. First, our patient population
was almost six times that in the French Aortic Plaques in
Stroke (FAPS) study, and more than 10 times larger than
those in the studies by Tunick and by Mitusch. Second, the
mean follow-up period in the present study was 3.2 years,
compared with 2.4, 1.4, and 1.2 years in the FAPS, the
Mitusch, and in the Tunick studies, respectively. Third, the
techniques used for detection of atherosclerotic disease and
the locations at which disease was sought differed. The three
previous studies evaluated, by use of TEE, atherosclerotic
disease of the aortic arch only. In the present study, only the
ascending aorta was evaluated, and we used epiaortic ultra-
sound. Although the utility of TEE for the detection of
atherosclerosis of the aortic arch and the descending tho-
racic aorta has been demonstrated (29–36), our group and
Konstadt et al. have shown that intraoperative visualization
of the ascending aorta is suboptimal with TEE as compared
with epiaortic ultrasound (38,55). Fourth, the patient pop-
ulations differ: we followed 1,957 consecutive patients
undergoing cardiac surgery, and of these, only 87 (4.4%) had
a history of a previous neurologic event. In the FAPS study,
all 331 patients were hospitalized for recent brain infarc-
tions, in the study of Tunick et al, over half of the 42
patients had suffered a previous vascular embolic event, and
in the study of Mitusch et al., over one third of the patients
had a history of thromboembolic disease. Since a history of
previous cerebrovascular event is known to be a predictor of
future events, it could be argued that there was selection bias
in these three studies. Fifth, the incidence of recurrent
neurologic events according to severity of aortic arch ath-
erosclerosis in the FAPS study was higher than in our study
(Table 5). This is likely due to differences in study popula-
tions and in duration of follow-up. Thus, our study confirms
the findings of the FAPS study, that the incidence of
neurologic events increases as the severity of aortic athero-
sclerosis increases. However, our study is unique because it
documents, for the first time, that increasing severity of
atherosclerotic disease of the ascending aorta is a significant
predictor of long-term mortality.
Atrial fibrillation and carotid artery disease. Atrial fibril-
lation and carotid artery disease have been associated with
an increased risk of neurologic events (6,7,11–12). In the
present study, 75% of patients underwent carotid artery
ultrasound, only 88 (6%) had .80% occlusion of one or
both carotid arteries, and most of these underwent carotid
artery endarterectomy in association with their cardiac
surgery. Even though severe carotid artery stenosis was a
univariate predictor of neurologic events and of all-cause
mortality, this variable was not a predictor in the multivar-
iate analysis. The small number of patients with uncorrected
severe carotid artery disease may explain why this was not a
predictor of subsequent neurologic events in our study. Our
findings do not contradict those of previous studies in which
severe carotid artery disease was found to be an independent
predictor of neurologic events.
Atrial fibrillation also has been shown to be an indepen-
dent predictor of neurologic events. In the present study, a
history of atrial fibrillation was a univariate predictor of
long-term neurologic events, but it was not a predictor in
the multivariate analysis. Since only 92 patients suffered
neurologic events, it is likely that statistical power is lacking
to definitively determine the independent predictive value of
atrial fibrillation for the development of neurologic events.
Pooled data from studies comparing treatment with warfa-
rin and placebo in patients with atrial fibrillation have
shown an event rate of approximately 4.5% per year in the
placebo group versus 1.4% in the warfarin group (56). Since
246 of the patients in the present study had a history of
atrial fibrillation on enrollment, approximately 30 neuro-
logic events attributable to atrial fibrillation would be
expected over a three-year follow-up, but only if atrial
fibrillation were left untreated. In the present study, most
patients with atrial fibrillation were treated with aspirin
and/or warfarin, which would mitigate against an effect of
atrial fibrillation on neurologic events.
Limitations of the study. Our study population was lim-
ited to cardiac patients who underwent cardiac surgery, but
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because of the known association between CAD, hyperten-
sion and neurologic events, the results of this study may be
generalizable to a large number of patients with these three
conditions, who are at high risk for suffering neurologic events.
In addition, a large number of deaths in patients with neuro-
logic events occur in this high-risk population (57,58).
The strength of the relationship found in this study
between aortic atherosclerosis and neurologic events may
have been limited by a number of factors. First, we collected
data on atherosclerosis of the ascending aorta only, not on
the aortic arch or the descending thoracic aorta. Studies
have documented that atherosclerotic disease in the aortic
arch or the descending aorta is associated with an increased
risk of stroke and/or peripheral vascular ischemic events
(33–36). If the association between cerebrovascular events
and atherosclerosis of the aortic arch is at least as strong as
the association observed between the former and ascending
aortic atherosclerosis, additional neurologic events could be
explained by atherosclerosis of the aortic arch in the absence
of disease in the ascending aorta. Thus, it is possible that the
true incidence of neurologic events associated with athero-
sclerosis of the aorta was underestimated. Second, even
though we obtained confirmation of the occurrence of
neurologic events (eg, we required neurologic confirmation
and/or hospital records clearly documenting the occurrence
of stroke or TIA) and mortality (eg, the death certificate) in
all cases, we were unable to determine the exact anatomic
location of some of the neurologic events. If we had been
able to confine our analysis to neurologic events that could
not have been explained by significant contralateral carotid
artery disease (in those who underwent carotid artery
ultrasound), it may have been possible to ascertain the
relative contribution of aortic atherosclerosis more defini-
tively. Third, some patients underwent alterations in the
surgical technique as a result of the epiaortic ultrasound
findings, which may have reduced the observed long-term
risk related to atherosclerosis of this vessel (24,25).
The therapeutic implications of the findings in this study
are unknown. Further investigation will be needed to define
better diagnostic strategies and to determine whether treat-
ment with anticoagulants and/or neuroprotective agents will
be effective in the prevention of atheroembolic neurologic
events in these high-risk patients (59,60).
Conclusions. In this prospective, long-term follow-up
study of 1,957 patients, we have shown that atherosclerosis
of the ascending aorta is an independent predictor of
neurologic events and of all-cause mortality. In addition to
being a direct cause of atheroembolism, the atherosclerotic
aorta may be a marker of generalized atherosclerosis and
thus of increased morbidity and mortality.
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